Who would really benefit from DPP-4 inhibitors?

Gian Paolo Fadini, Saula Vigili de Kreutzenberg, Romelda Gjini, Angelo Avogaro, The metabolic syndrome influences the response to incretin-based therapies. Acta Diabetologica. ,vol. 48, pp. 219- 225 ,(2011) , 10.1007/S00592-011-0296-7

Yoshimasa Aso, Noriyuki Ozeki, Tomoko Terasawa, Rika Naruse, Kenji Hara, Mariko Suetsugu, Kohzo Takebayashi, Mitsuei Shibazaki, Kohsuke Haruki, Kimio Morita, Toshihiko Inukai, Serum level of soluble CD26/dipeptidyl peptidase-4 (DPP-4) predicts the response to sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes controlled inadequately by metformin and/or sulfonylurea. Translational Research. ,vol. 159, pp. 25- 31 ,(2012) , 10.1016/J.TRSL.2011.09.005

Matteo Monami, Francesco Cremasco, Caterina Lamanna, Niccolò Marchionni, Edoardo Mannucci, Predictors of response to dipeptidyl peptidase-4 inhibitors: evidence from randomized clinical trials. Diabetes-metabolism Research and Reviews. ,vol. 27, pp. 362- 372 ,(2011) , 10.1002/DMRR.1184

Nasser Mikhail, Use of Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease Postgraduate Medicine. ,vol. 124, pp. 138- 144 ,(2012) , 10.3810/PGM.2012.07.2575

Benjamin M Scirica, Deepak L Bhatt, Eugene Braunwald, P Gabriel Steg, Jaime Davidson, Boaz Hirshberg, Peter Ohman, Robert Frederich, Stephen D Wiviott, Elaine B Hoffman, Matthew A Cavender, Jacob A Udell, Nihar R Desai, Ofri Mosenzon, Darren K McGuire, Kausik K Ray, Lawrence A Leiter, Itamar Raz, Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus The New England Journal of Medicine. ,vol. 369, pp. 1317- 1326 ,(2013) , 10.1056/NEJMOA1307684

William B White, Christopher P Cannon, Simon R Heller, Steven E Nissen, Richard M Bergenstal, George L Bakris, Alfonso T Perez, Penny R Fleck, Cyrus R Mehta, Stuart Kupfer, Craig Wilson, William C Cushman, Faiez Zannad, None, Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes The New England Journal of Medicine. ,vol. 369, pp. 1327- 1335 ,(2013) , 10.1056/NEJMOA1305889

Katherine Esposito, Paolo Chiodini, Annalisa Capuano, Maria Ida Maiorino, Giuseppe Bellastella, Dario Giugliano, Baseline glycemic parameters predict the hemoglobin A1c response to DPP-4 inhibitors : meta-regression analysis of 78 randomized controlled trials with 20,053 patients. Endocrine. ,vol. 46, pp. 43- 51 ,(2014) , 10.1007/S12020-013-0090-0